| Trial name or title |
Effectiveness of Escitalopram in the Treatment of Body Dysmorphic Disorder |
| Methods |
Open‐label phase, during which all participants will receive escitalopram for 14 weeks, followed by randomized, double‐blind, placebo control, parallel assignment, efficacy study |
| Participants |
DSM‐IV diagnosis of BDD within 6 months of study start, score higher than 24 on BDD‐YBOCS, alcohol abuse or dependence within 3 months prior, not suicidal or homicidal, expected number: 128 |
| Interventions |
Escitalopram (Lexapro) versus placebo |
| Outcomes |
Relapse of Body Dysmorphic Disorder Symptoms, Month 6
Functioning and life satisfaction, Depressive symptoms, Anxiety symptoms |
| Starting date |
May 2005 |
| Contact information |
Kara L. Watts; tel: 617‐643‐3079; KLWatts@partners.org |
| Notes |
Study ID numbers: R01 MH72854 ; 2004‐P‐002305 ; DSIR 83‐ATSO |
